Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. reports recurring developments in cell analysis instruments, reagents, services, and financial performance. The company uses patented Full Spectrum Profiling™ (FSP®) technology to analyze fluorescence signals in flow cytometry and related cell analysis workflows.
News about Cytek Biosciences commonly covers earnings releases, revenue trends, recurring service and reagent revenue, instrument placements, product platforms such as Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS, Cytek Aurora™ Evo, Cytek Orion™, ESP™ detection technology, and Amnis® and Guava® products, as well as investor conference participation and business outlook updates.
Cytek Biosciences (Nasdaq: CTKB), a leading cell analysis solutions company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management will deliver a presentation on Thursday, January 16th at 8:15 a.m. Pacific Time (11:15 a.m. Eastern Time).
Investors and interested parties can access both live and archived versions of the presentation through the 'Investors' section of Cytek's website at investors.cytekbio.com.
Cytek Biosciences (CTKB) has announced a new $50 million stock repurchase program for 2025, succeeding its current program expiring December 31, 2024. The new program will run from January 1 to December 31, 2025, unless modified by the Board of Directors. Repurchases will be conducted in the open market and/or through private negotiations, in compliance with SEC Rule 10b-18. The timing and amount of repurchases will depend on factors including liquidity, cash flow, and market conditions. The company maintains discretion to modify or suspend the program at any time.
Cytek Biosciences (Nasdaq: CTKB) announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). A live and archived webcast of the presentation will be available to interested parties through the 'Investors' section of Cytek's website at investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) has been named 'Overall BioTech Company of the Year' in the 2024 BioTech Breakthrough Awards program, which attracted nominations from 14 countries. The company is recognized for its pioneering work in spectral flow cytometry and its Full Spectrum Profiling™ technology. Cytek's platform includes the Aurora™ and Northern Lights™ systems, the Aurora™ CS cell sorter, and Amnis® and Guava® branded products. The company's impact is evidenced by over 2,100 peer-reviewed articles and its commitment to making flow cytometry more accessible for research and clinical applications.
Cytek Biosciences (CTKB) has launched the world's first Enhanced Small Particle (ESP™) Detection Option for its Aurora™ CS cell sorter system. This groundbreaking technology enables detection and sorting of particles as small as 70 nm, including exosomes and extracellular vesicles (EVs). The system builds on Cytek's Full Spectrum Profiling™ technology and allows seamless assay transfer from analyzer to sorter. This advancement is particularly significant for research in drug delivery, cell therapy, disease diagnostics, and vaccine delivery, enabling researchers to analyze materials previously impossible to sort.
Cytek Biosciences (CTKB) reported Q3 2024 financial results with total revenue of $51.5 million, up 7% year-over-year and 10% quarter-over-quarter. The company achieved $143.0 million in year-to-date revenue, 6% above the same period in 2023. Notable developments include the launch of SpectroPanel™ tool and expansion of installed base to 2,821 instruments. Q3 showed a net income of $0.9 million, improving from a $6.5 million loss in Q3 2023. The company maintains its 2024 revenue guidance of $203-210 million, projecting 5-9% growth. Cash position remained strong at $277.8 million, with $12.1 million used for share repurchases during Q3.
Cytek Biosciences (Nasdaq: CTKB) has announced its participation in two major investor conferences in November 2024. The company will present at the Guggenheim Inaugural Healthcare Conference in Boston on November 11 at 11:00 a.m. ET, featuring a fireside chat. Additionally, they will deliver a presentation at the UBS Global Healthcare Conference in Rancho Palos Verdes on November 13 at 4:15 p.m. PT. Both presentations will be accessible via live and archived webcasts on the company's investor relations website.
Cytek Biosciences (Nasdaq: CTKB) has announced it will release its third quarter 2024 financial results after market close on Tuesday, November 5, 2024. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss results, business developments, and outlook. The webcast will be accessible through the Investors section of Cytek's website.
Cytek Biosciences (Nasdaq: CTKB) is set to showcase its Full Spectrum Profiling™ (FSP™) technology at two major clinical conferences: the European Society for Clinical Cell Analysis (ESCCA) 2024 Conference in September and the 39th International Clinical Cytometry (ICCS) Meeting & Course in October. At ESCCA, Dr. Nicholas McCarthy will lead a symposium on streamlining AML-MRD analysis using a 21-color antibody panel for the Cytek® Northern Lights™- CLC flow cytometer. At ICCS, Dr. David Ng will host a Lunch and Learn session, highlighting how spectral flow cytometry has improved efficiency in resource- laboratories, reducing reagent consumption and streamlining processes.
Cytek Biosciences (Nasdaq: CTKB) announced the resignation of its Chief Operating Officer, Chris Williams, effective September 27, 2024. Williams is leaving to accept a CEO position at another company. Instead of replacing the COO role, Cytek will restructure to create a flatter, more efficient management structure.
During his tenure, Williams played key roles in the company's growth, improving operational processes and enhancing efficiency. CEO Dr. Wenbin Jiang expressed gratitude for Williams' contributions and sees the restructuring as an opportunity to increase agility and empower teams. Williams will remain with Cytek until his departure date to ensure a smooth transition and assist with the restructuring process.